Gallium-68-HBED PSMA

Drug Profile

Gallium-68-HBED PSMA

Alternative Names: (68Ga)PSMA-HBED-CC - Radiopharmacus; 68Ga-HBED-CC-PSMA - Radipharmacus; HBED-PSMA-Ga68 - Radiopharmacus; PSMA-HBED-CC GA-68 - Radiopharmacus

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Radiopharmacus
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 01 Dec 2016 Radiopharmacus plans a phase III trial for Prostate cancer (diagnosis) in Brazil (RBR26w4cr)
  • 01 Oct 2016 Preclinical trials in Prostate cancer (Diagnosis) in Brazil (IV) before October 2016 (RBR26w4cr)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top